| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
B Inhibitors as Potential Novel Anti-Inflammatory Agents for the Treatment of Immune Glomerulonephritis
From the Renal and Vascular Research Laboratory,* Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain; the Hospital Clínico San Carlos, Madrid, Spain; and the Kidney Disease Section, National Institutes of Health, Bethesda, Maryland
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
B regulates several genes implicated in the inflammatory response and represents an interesting therapeutic target. We examined the effects of gliotoxin (a fungal metabolite) and parthenolide (a plant extract), which possess anti-inflammatory activities in vitro, on the progression of experimental glomerulonephritis. In the anti-Thy 1.1 rat model, gliotoxin (75 µg/rat/day, 10 days, n = 18 rats) markedly reduced proteinuria, glomerular lesions, and monocyte infiltration. In anti-mesangial cell nephritis in mice, parthenolide (70 µg/mouse/day, 7 days, n = 17 mice) significantly decreased proteinuria, hematuria, and glomerular proliferation. NF-B activity, localized in glomerular and tubular cells, was attenuated by either gliotoxin or parthenolide, in association with diminished renal expression of monocyte chemoattractant protein-1 and inducible nitric oxide synthase. In cultured mesangial cells and monocytes, gliotoxin and parthenolide inhibited NF-B activation and expression of inflammatory genes induced by lipopolysaccharide and cytokines, by blocking the phosphorylation/degradation of the IB
subunit. In summary, gliotoxin and parthenolide prevent proteinuria and renal lesions by inhibiting NF-B activation and expression of regulated genes. This may represent a novel approach for the treatment of immune and inflammatory renal diseases.
B. NF-B can be activated in several cell types by numerous physiological and pathological stimuli, such as cytokines, mitogens, virus, mechanical and oxidative stress, and chemical agents.2,3
Studies in experimental and human nephritis have provided evidence supporting the involvement of NF-B in the pathogenesis of glomerulonephritis.4-6
In addition, expression of NF-B-dependent genes, such as chemokines, adhesion molecules, inducible nitric oxide synthase (iNOS), and cyclooxygenase has been demonstrated in cultured glomerular cells, including mesangial cells (MCs).7-9
The family of NF-B proteins shares a conserved central region, the Rel domain, involved in the dimerization and interaction with the inhibitory subunit IB, nuclear translocation, and DNA binding. The five members of this family (p50/p105, p65/RelA, c-Rel, RelB, and p52/p100) associate in different dimeric forms. The classic heterodimer is composed of p50 and p65.10
In resting cells, NF-B dimers remain in the cytoplasm as an inactive form bound to the inhibitory subunit IB. The IB family comprises IB (bound to the p50-p65 dimer and related with transient activation of NF-B), IBß (implicated in a more stable activation), and IB
.10,11
Upon stimulation, IB is phosphorylated by the IB kinase (IKK) complex, ubiquitinated, and ultimately degraded by the proteasome system. Then, free NF-B dimers expose the nuclear localization sequence and translocate into the nucleus, where they activate the transcription of target genes.4,10,11
The pharmacological modulation of the inflammatory responses is the main objective in the design of anti-inflammatory drugs. Various drugs, such as steroids and aspirin, are effective in inhibiting NF-B-inducible gene expression.3,5,12,13
In general, the strategies regulating NF-B can be classified in relation with the step in the NF-B pathway: antioxidants,14
protease inhibitors,15
nuclear translocation inhibitors,16
and DNA binding blockers.17
Antioxidants are the most frequently used and inhibit chemokine expression in cultured renal cells,8,18
and prevent proteinuria and cytokine expression in experimental nephritis.19
Recently, several natural products, such as gliotoxin and parthenolide, have been emerged as possible anti-inflammatory agents.20,21
Gliotoxin, a metabolite from the fungus Aspergillus fumigatus, inhibits the activation and phagocytosis in leukocytes and the catalytic activity of 20S proteasome, and can also induce apoptosis.20,22-25
Parthenolide, a sesquiterpene lactone derived from Mexican-Indian medicinal plants, inhibits the gene expression of interleukin-8, iNOS, and cyclooxygenase in several cell lines.26-28
Previous studies reported that low doses of gliotoxin and parthenolide prevent the activation of NF-B by a variety of stimuli in cultured cells,29-31
but the mechanisms of their potential anti-inflammatory effects, and the possible use in inflammatory and immune diseases are not well examined.
Because many forms of primary glomerulonephritis do not consistently respond to current therapy, in this study we attempted novel therapeutic approaches for these diseases, focusing on NF-B as a possible target. Our purpose is to modify in vivo the expression of proinflammatory genes by using novel NF-B inhibitors. First, we evaluated the effects of gliotoxin and parthenolide on NF-B activation and expression of regulated genes (MCP-1 and iNOS) in cultured MCs and monocytes stimulated with inflammatory stimuli. Second, we analyzed whether these inhibitors modulate (or prevent) the initiation and progression of glomerular injury in two experimental models of mesangial proliferative glomerulonephritis. The administration of these agents could represent a novel therapeutic approach to progressive glomerulonephritis.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Gliotoxin, parthenolide, and lipopolysaccharide (LPS) were purchased from Sigma Chemical Co. (St. Louis, MO). The cytokines [human tumor necrosis factor- (TNF-), human interferon-
(IFN-) and human interleukin-1ß (IL-1ß)] were purchased from Immunogenex Corp. (Los Angeles, CA). The specific antibodies (Abs) used were as follows: pIB, IB, p65, and c-Rel (Santa Cruz Biotechnology, Santa Cruz, CA), ED1 (Serotec, Oxford, UK), BrdU (Calbiochem, La Jolla, CA), iNOS and p50 (Chemicon International, Temecula, CA), fluorescein isothiocyanate-labeled IgG (The Binding Site, Birmingham, UK), peroxidase-labeled IgG (Amersham, Buckinghamshire, UK), and alkaline phosphatase-labeled IgG (Roche, Barcelona, Spain).
Cell Cultures
MCs from human and rat kidneys32 were cultured in RPMI 1640 with 25 mmol/L HEPES, pH 7.4, 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mmol/L glutamine (Life Technologies, Paisley, Scotland) and characterized by phase contrast microscopy, positive staining for desmin and vimentin, and negative staining for factor VIII and cytokeratin. The human monocytic cell line THP-1 [American Type Culture Collection (ATCC), Rockville, MD] was cultured in RPMI with 10% FCS. Cells were made quiescent by 24 hours of incubation in medium with 0.5% FCS, then preincubated for 90 minutes with the inhibitors, and washed before stimulation with LPS and cytokines. Cell viability was assessed by trypan blue exclusion.
Electrophoretic Mobility Shift Assay (EMSA)
Cell nuclear proteins (10 µg) were incubated in buffer containing 50 µg/ml of poly(dI-dC) (Amersham), and 0.035 pmol of [32P]NF-B or [32P]AP-1 consensus oligonucleotides, and the reactions were analyzed on a 4% nondenaturing polyacrylamide gel and autoradiographed. Specificity of the binding reaction was confirmed using a 100-fold excess of unlabeled probe. NF-B subunits were identified by incubation with Abs against p50, p65, and c-Rel.8
Western Blot Analysis
Cytosolic proteins (20 µg) were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Immobilon P; Millipore, Bedford, MA). Membranes were blocked with 5% nonfat milk, and then incubated with 10 µg/ml of goat anti-IB or 1 µg/ml of monoclonal anti-pIB, followed by peroxidase-conjugated secondary Ab and chemiluminescent detection system.
Cell Proliferation Assay
Human MCs were pretreated for 90 minutes with serial dilutions of inhibitors, then washed and incubated for an additional 24 hours in medium containing 10% FCS. Cell proliferation was determined in 96-well plates by colorimetric assay of methylene blue incorporation.33 Alternatively, cell proliferation was studied after 24 hours of incubation in medium with 10% FCS and inhibitors. Data were expressed as percentage of proliferating cells in relation to control conditions.
Analysis of mRNA Expression
Total RNA from cells and tissues was obtained by the acid guanidine-thiocyanate-phenol-chloroform method. In cultured cells, MCP-1 mRNA expression was analyzed by Northern blot using cDNA probes for human MCP-1 and 28S ribosomal RNA (JE/pGEM-hJE34 and HHCD07; ATCC). Membranes containing RNA were hybridized, autoradiographed, and densitometered. Relative amounts of MCP-1 were established in relation to 28S. In renal tissues the mRNA expression was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) using the following primers: rat MCP-1 sense, 5'-TTCTGGGCCTGTTGTTCACA-3'; anti-sense, 5'-GGTCACTTCTACAGAAGTCC-3'; mouse MCP-1 sense, 5'-AGCACCAGCCAACTCTCACT-3'; anti-sense, 5'-TCTGGACCCATTCCTTCTTG-3'; rat iNOS sense, 5'-CTTCAACCCCAAGGTTGTCTGCAT-3'; anti-sense, 5'-ATGTCATGAGCAAAGGGGCAGAAC-3'. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control.
Determination of Nitrites
NO released from cells was determined by the accumulation of nitrites and measured by fluorescent reaction with 1 mmol/L of 2,3-diaminonaphthalene.34 The absorbance at 548 nm was measured and compared with a standard of NaNO2, and data were expressed as nmol NO2-/mg protein.
Transient Transfection and Luciferase Assay
Growth-arrested cells (1 x 105) were co-transfected with piNOS-Luc (a gift from Dr. Santiago Lamas; CIB, Madrid, Spain)9 and a normalizing reporter vector (pRL-TK with the Renilla luciferase gene; Promega, Madison WI) by using the FuGENE reagent (Roche) and then stimulated for 24 hours. The luciferase activity in cleared lysate was assayed using a luminometer. Luciferase activity was normalized by total protein concentration and variations in transfection efficiency.
Isolation of Anti-MC Abs
Monoclonal Ab (IgG1) against rat mesangial antigen Thy 1.1 was isolated from ascitic BALB/c mice injected with hybridome cells OX-7 (European Collection of Cell Cultures, Salisbury, UK) by affinity chromatography on protein G-Sepharose. Anti-murine MC serum was obtained by sheep immunization with protein extract form SV40-transformed mouse cells MES13 (Yo Y, Mobaraki H, Lu H, Braun M, Owens J, King C, Kopp JB, manuscript submitted). Control serum was obtained from sheep before immunization. For all experiments, sera were decomplemented by heating at 56° for 30 minutes.
Experimental Models of Mesangial Proliferative Glomerulonephritis
Anti-Thy 1.1 nephritis was induced in male Sprague-Dawley rats (200 g) at day 0 by injection of anti-Thy1.1 IgG (5 mg/kg in 350 µl of phosphate-buffered saline) into a tail vein. Mesangial glomerulonephritis was induced in female C57/BL6 mice (18 to 20 g) at day 0 by injection of sheep anti-murine MC antiserum (200 µl/20 g body weight). Groups of study: I, rats (n = 18) and mice (n = 17) treated daily with gliotoxin (75 µg/200 g body weight, i.p.) and parthenolide (70 µg/20 g body weight, i.p.), respectively; II, rats (n = 20) and mice (n = 10) with spontaneous development of nephritis with injection of vehicle (saline); III and IV, healthy control rats (n = 17) and mice (n = 8) receiving the respective amount of inhibitors and saline. Treatment with gliotoxin or parthenolide was started the day before and followed for 10 or 7 days, respectively. Urine samples were taken at regular intervals starting on day 0. Proteinuria was measured by the sulfosalicylic method (rats) or the Knight’s method (mice).35 Urinary hemoglobin was measured by Aution sticks (Arkray Factory, Shiga, Japan). All studies were performed in accordance to the European Union normative. Animals were sacrificed at days 2, 4, 7, and 10 (rat model) and days 5 and 7 (mouse model).
Kidney Histology and Immunostaining
Light microscopic analysis of renal cortex was performed on paraffin sections (5-µm thick) stained with hematoxylin and eosin, and Masson’s trichrome. The examination of infiltrating cells (ED1+, rat macrophage) and iNOS production was performed by indirect immunoperoxidase. For determining proliferating cells, mice were intraperitoneally injected with 2 mg of BrdU for 16, 8, and 4 hours before sacrifice, and then immunoperoxidase staining with anti-BrdU was performed on paraffin-embedded samples.
In Situ Detection of Activated Transcription Factors
Paraffin-embedded tissue sections fixed in 0.5% paraformaldehyde were incubated with 50 pmol of digoxigenin-labeled NF-B and AP-1 probes in buffer containing 0.25% bovine serum albumin and 1 µg/ml of poly(dI-dC), followed by alkaline phosphatase-conjugated anti-digoxigenin IgG and colorimetric detection. A 200-fold excess of unlabeled probe was used to test the specificity of the technique.36
Evaluation of Tissue Staining and Statistical Analysis
Semiquantification of morphological changes in the animal models was made in regard to glomerular lesions (number of glomeruli with hypercellularity, mesangiolysis, or immune deposits/30 glomeruli), tubular lesions (number of tubules with atrophy or degeneration/20 fields at x40 magnification), and interstitial infiltration (number of focus/20 fields at x40 magnification). Samples from each animal were examined in a blinded manner, and semiquantitatively graded on a scale from 0 to 3. Quantification of iNOS staining and infiltrating/proliferating cells was made by determining the total number of positive-labeled cells in 20 randomly chosen areas. The results are given as mean ± SD or representative experiments, when indicated. Values were analyzed by ANOVA and Tukey-Kramer tests using Instat (Graphpad Software, San Diego, CA). A P value <0.05 was considered significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
B in MCs and Monocytes
Human MCs were preincubated for 90 minutes with parthenolide or gliotoxin (1 to 3 µg/ml), then washed and incubated for 1 hour with the combination of LPS (10 µg/ml) and cytokines (TNF-, 100 ng/ml; IFN-, 100 U/ml; and IL-1ß, 100 U/ml). NF-B activity in nuclear extracts was analyzed by EMSA. As indicated in Figure 1A
, the strong DNA-binding activity induced by LPS/cytokines (8-fold increase versus control) was dose dependently attenuated by gliotoxin and parthenolide (75 ± 6% and 69 ± 9% inhibition at 3 µg/ml, respectively). Gliotoxin and parthenolide did not inhibit the activation of other transcription factors, such as AP-1 (Figure 1A)
. Similar results were observed in nuclear extracts from rat MCs pretreated with gliotoxin or parthenolide (1 µg/ml) and then stimulated with 1 µg/ml of LPS (69 ± 8% and 72 ± 8% inhibition, respectively, n = 3). In the monocytic cell line THP-1, NF-B activation induced by LPS/cytokines was also prevented by treatment with 1 µg/ml of gliotoxin and 2.5 µg/ml of parthenolide (79 ± 4% and 73 ± 12% inhibition, n = 3). In some cases, extracts from stimulated cells were incubated with gliotoxin or parthenolide before EMSA. Both inhibitors, even at higher doses, did not influence the interaction of NF-B complex with the consensus oligonucleotide in vitro (not shown). These data exclude the possibility that both agents directly affect the DNA-binding ability of activated NF-B.
|
B activation was also evaluated by measuring phosphorylation and degradation of the inhibitory subunit IB. Western blot analysis of cytosolic proteins from LPS/cytokine-stimulated human MCs revealed an increase in phosphorylated IB and a subsequent degradation of IB (Figure 1B)
. Preincubation with parthenolide prevented the phosphorylation and degradation of IB, whereas gliotoxin did not affect phosphorylation but protected IB from proteolysis (Figure 1B)
. The effects of both agents on monocytic NF-B activation were very similar (not shown). These results suggested that IB is the common step in the signaling cascade leading to NF-B activation that is targeted by gliotoxin and parthenolide. Effects of Gliotoxin and Parthenolide on Cell Viability and Proliferation
By trypan blue exclusion we observed that more than 95% of cells (MC and THP-1) were viable after 90 minutes of treatment with 1 µg/ml of gliotoxin. Viability remained high (>75%) at 3 µg/ml, but a toxic effect was noted using concentrations >5 µg/ml (viability around 30%). No toxic effect was observed with parthenolide even at doses up to 6 µg/ml.
In proliferation assays (methylene blue incorporation) we observed that preincubation for 90 minutes with serial dilutions of gliotoxin and parthenolide (from 0.75 to 12 µg/ml) did not diminish the number of proliferating MCs (maximal percentages of inhibition: 23 ± 4% and 16 ± 3%, respectively). MC proliferation was only inhibited by using gliotoxin at higher doses and longer incubation periods (24 µg/ml at 24 hours, 66 ± 8% inhibition, n = 4).
Gliotoxin and Parthenolide Inhibit the Expression of NF-B-Regulated Genes
In these experiments we checked the effects of these agents on the expression of genes transcriptionally regulated by NF-B, such as MCP-1 and iNOS.7-9
In human MCs, preincubation with gliotoxin or parthenolide (1 µg/ml) prevented the MCP-1 mRNA expression induced by LPS/cytokines (72% and 58% inhibition; Figure 2A
). In a reported gene assay using human MCs transfected with piNOS-Luc plasmid, both agents inhibited the activation of the iNOS promoter induced by LPS/cytokines (75% inhibition, Figure 2B
). According to this data, the mesangial production of nitrites induced by LPS/cytokines after 24 hours was also decreased by treatment with gliotoxin and parthenolide (79% and 74% inhibition, Figure 2C
). In THP-1 cells, gliotoxin down-regulated the MCP-1 mRNA expression (69 ± 7% inhibition n = 3), and parthenolide decreased the iNOS transcription (69 ± 3% inhibition at 24 hours, n = 3), and the NO generation induced by LPS/cytokines (183 ± 11 versus 52 ± 7 nmol/mg protein at 24 hours, n = 4, P < 0.05).
|
Because both gliotoxin and parthenolide can inhibit NF-B activation and regulated-genes in cultured cells, we designed studies to examine their in vivo effect in experimental models of mesangial proliferative glomerulonephritis.
The evolution of urinary protein excretion in rats with anti-Thy 1.1 nephritis is shown in Figure 3A
. Proteinuria slightly increased until day 4 (39 ± 6 mg/24 hours), and thereafter decreased to control levels. Daily treatment with gliotoxin (75 µg/day) prevented the development of proteinuria, with nonsignificant differences between gliotoxin-treatment and healthy control groups. Previous studies have shown that the injection of anti-Thy 1.1 Ab in rats is associated with an acute complement-dependent mesangiolysis, followed by a MC proliferation phase that begins at day 2, peaks between days 3 and 5, and is resolved by day 14.37,38
This pattern was observed in vehicle-treated rats (Figure 3B)
, with a marked increase in the glomerular cell number, interstitial cell infiltration, and tubular atrophy compared with normal rats. The glomerular damage quantification after Masson’s staining is summarized in Table 1
. Gliotoxin treatment drastically reduced the excessive mesangial proliferative response (65% inhibition at day 7), the collapse of capillaries and the tubular atrophy (Figure 3C)
. Gliotoxin also significantly reduced the early glomerular influx of monocytes/macrophages (Table 1)
. Normal animals receiving daily injection of gliotoxin (ranging from 75 to 200 µg/rat) for 10 days did not show any toxic symptoms or renal morphological changes when compared with normal rats injected with saline, used as control (Table 1)
.
|
|
B activation in vivo was analyzed by EMSA. Extracts from nephritic rats showed a marked increase in the intensity of the NF-B bands at day 2, that remained elevated until 10 days after injection of the Abs. Gliotoxin administration attenuated this activation (Figure 4A)
. The composition of activated complexes (p50/p65 heterodimer, without c-Rel subunit) was not different between untreated nephritic and gliotoxin-treated rats, as determined by supershift assay (not shown).
|
B in the kidneys was analyzed in situ by Southwestern histochemistry. Very weak nuclear staining was observed in kidneys from healthy rats receiving daily injection of gliotoxin (Figure 4B)
or its vehicle (not shown), as control. In nephritic rats, NF-B activation increased (Figure 4C)
and was widely distributed in glomerular (mesangial and infiltrating cells), tubular (proximal and distal), and interstitial infiltrating cells. In gliotoxin-treated rats, the number and intensity of positive cells were decreased (Figure 4D)
. Specificity was verified in samples from nephritic animals by competition with unlabeled probe (Figure 4E)
.
We analyzed the effect of gliotoxin on expression of NF-B-dependent genes. Our results revealed increased MCP-1 mRNA levels in renal cortex of nephritic rats, maximal at day 4 (Figure 5)
, in temporal association with the ED1+ cell infiltration (Table 1)
, that was reduced by gliotoxin treatment (76% inhibition, Figure 5
). Similarly, the iNOS mRNA expression increased with the severity of the disease and was attenuated in the gliotoxin-treated group (Figure 5)
. By immunohistochemistry we observed an increase in iNOS protein in the glomeruli of nephritic animals (mesangial and infiltrating cells), that was diminished by gliotoxin treatment (glomerular score, day 4: control, 0.7 ± 0.2; untreated nephritis, 2.8 ± 0.2, P < 0.001 versus control; gliotoxin treatment, 1.3 ± 0.2, P < 0.01 versus nephritis).
|
Injection of sheep anti-mouse MC serum to normal mice was associated with mesangial deposition of heterologous sheep Ab leading to acute glomerulopathy characterized by severe proteinuria and hematuria. This model, similar to the anti-Thy 1.1 nephritis in rats, is characterized by a phase of reduced glomerular cell number followed by a phase of restorative cell proliferation (Yo Y, Mobaraki H, Lu H, Braun M, Owens J, King C, Kopp JB, submitted). Pathological proteinuria was even detected on day 1 (Figure 6A)
, and histological changes were maximal on day 5 (Figure 6, B and C)
. No pathological reactions (proteinuria and glomerular lesions) were observed with control nonimmune serum (not shown).
|
30% of mice. Thus, these findings, together with the in vitro data revealing nontoxic effects of parthenolide on cultured MCs, led us to investigate the effects of parthenolide in the mouse model. Mice injected with anti-murine MCs and receiving daily parthenolide treatment (70 µg/day) developed less proteinuria than the untreated mice did (Figure 6A)
. Hematuria was also decreased by the treatment (1.2 ± 0.6 versus 3.4 ± 0.4 score at day 5; 0.2 ± 0.1 versus 3 ± 0.8 at day 7; P < 0.05). Likewise, the morphological lesions including glomerular (hypercellularity, mesangial expansion, matrix accumulation, and deposits), tubular (atrophy, epithelial degeneration, cast and cell infiltration around the damaged tubules) and interstitial areas (fibrosis and infiltrates) were significantly reduced by the treatment (Figure 6; B, C, D)
. No adverse reactions were observed in either control or nephritic mice receiving this dose of parthenolide. Glomerular cell proliferation (BrdU+ cells) was increased in mice with glomerulonephritis at days 5 and 7 when compared with controls, whereas parthenolide treatment was associated with a marked reduction in the number of glomerular proliferating cells (Figure 7)
.
|
B was observed at days 5 and 7 as assessed by in vitro and in situ oligonucleotide hybridization, with a wide distribution in glomerular, tubular, and infiltrating cells (Figure 8, A and B)
. Treatment with parthenolide prevented the activation of this transcription factor, detecting levels near to control animals in all cell types (61% inhibition at day 7; Figure 8, A and C
). Parthenolide administration also reduced the increased mRNA expression of MCP-1 detected in this model of glomerulonephritis, as determined by RT-PCR analysis (increases versus control: untreated nephritis, 2.6-fold; parthenolide treatment, 1.1-fold; n = 4). In this experimental model, the activation of other transcription factors, such as AP-1, was also investigated. Although induction of the nephritis caused activation of AP-1 (Figure 8D)
, no decrease in the intensity and number of AP-1-positive cells were observed after parthenolide treatment (Figure 8E)
, confirming the specificity of this compound for NF-B pathway.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
B activation and expression of NF-B-dependent genes, both in renal resident and infiltrating cells, thus confirming the participation of this transcription factor in the pathogenesis of mesangial proliferative glomerulonephritis, as previously reported in other human and experimental nephritis.4,6,13,19,39,40
The wide spectrum of immunologically relevant genes regulated by NF-B and the studies of NF-B-deficient mice had emphasized the importance of this transcription factor as a mediator of immune and inflammatory responses.10
In this regard, several drugs have emerged as potential NF-B modulators, although their mechanisms are not well described.3-5,13-15
New promising strategies include cell-permeable peptides containing the nuclear localization domain and decoy double-stranded oligonucleotides, with the ability to inhibit NF-B nuclear translocation and gene transactivation, respectively.16,17,41
However, it is important to identify new compounds with specificity for this activation pathway without affecting other routes of cell signaling.
The NF-B pathway is regulated by diverse transduction cascades. One important step is IB phosphorylation mediated by the IKK complex (kinase subunits and ß, and regulatory subunit ), leading to ubiquitination and subsequent degradation by the 26S proteasome. Then free NF-B complexes translocate into the nucleus, bind to target DNA elements, and regulate gene transcription.10,11
Based on that, we hypothesized that the inhibition of IB proteins could be a possible target for specific therapies. In this sense, the use of gliotoxin and parthenolide could be more reasonable, because their inhibitory action is due to, at least partially, the blockade of the IB phosphorylation/degradation pathway. In this work we demonstrate in cultured renal cells that both inhibitors, at nontoxic doses, modulate the NF-B activation induced by inflammatory stimuli (LPS and cytokines) and the expression of NF-B-regulated genes (iNOS and MCP-1). The inhibitory effects of both agents seem to be specific for NF-B, because they did not influence the activity of other transcription factors, as previously reported.29,30
This inhibition of DNA binding was paralleled by the prevention of IB degradation. In addition, determination of phosphorylated IB levels revealed a loss of induced phosphorylation in the presence of parthenolide, but not gliotoxin. Both inhibitors act at short periods and relatively low concentrations, suggesting a rapid cell absorption and persistent effect.
The in vivo effects of gliotoxin and parthenolide were examined in experimental models of mesangial proliferative glomerulonephritis. The inflammatory response of rats and mice receiving daily injections of these agents was lower than those of untreated animals, as demonstrated by reduced proteinuria and glomerular lesions. The treatment was also effective in the prevention of glomerular recruitment of mononuclear cells and excessive mesangial proliferation. Indeed, the activation of NF-B in glomeruli and tubules of nephritic animals, as well as the renal expression of iNOS and MCP-1, were importantly attenuated by the treatment. To our knowledge, this is the first study to show the anti-inflammatory properties of gliotoxin and parthenolide administration in renal diseases. Other authors reported that, in dextran sodium sulfate-induced colitis in rodents, gliotoxin reduced the disease activity and colonic levels of inflammatory cytokines.42,43
Gliotoxin also presented immunomodulating activity for the prevention of autoimmune diabetes mellitus in rats.44
To date, there are no reports describing the in vivo effects of parthenolide.
The molecular mechanisms of gliotoxin and parthenolide are not well established. Parthenolide could interfere with some enzymes of the IB phosphorylation complex, probably with the regulating subunit IKK or other not yet identified proteins.31
A recent report speculates that sesquiterpene lactones directly alkylate the p65 subunit of NF-B, thereby inhibiting DNA binding.45
In the future, binding assays using radiolabeled parthenolide could help to identify the structures that this inhibitor may inactivate. Moreover, gliotoxin decreases the expression of NF-B-dependent genes, such as chemokines, cytokines, and adhesion molecules in several cell types29,42,43,46,47
and inhibits specifically the activation of NF-B by blocking the degradation of IB.29
However, gliotoxin may also cause the inactivation of other enzymes in different signaling cascades. This fact probably explains its narrow therapeutic range43
and potential side effects, such as induction of apoptosis.20
In this sense, recent reports indicate that gliotoxin induces apoptosis in murine macrophages in a dose-dependent and cell cycle-independent manner23
and inhibits proliferation of human umbilical vein endothelial cells and macrophages.24,48
In summary, our data show that gliotoxin and parthenolide reduce inflammatory responses in experimental glomerulonephritis, such as mononuclear cell infiltration and MC proliferation. These agents may exert their effects through the blockade of NF-B activation and subsequent expression of inflammatory genes. Our findings support the idea that drugs modulating NF-B may represent a novel therapeutic approach in progressive renal diseases and other inflammatory conditions. Moreover, the potential selective effect of these new compounds could represent an additional advantage, allowing to approach separately the different intracellular signaling cascades.
|
Footnotes |
|---|
Supported by the Fondo de Investigaciones Sanitarias (grants FIS 99/0425, 00/0111), the Comunidad de Madrid (grants 08.3/0002/1998, 08.4/0019.1/2000), the Spanish Society of Nephrology, and the Japan Health Science Foundation and Alumni Association of Juntendo University (to Y. S.).
Accepted for publication June 28, 2002.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999, 45:7-17B: important transcription factor and therapeutic target. J Clin Pharmacol 1998, 38:981-993B (NF-B) and renal disease. Kidney Int 2001, 59:415-424[Medline]
B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats. Biochim Biophys Acta 1997, 1362:252-262[Medline]
B correlates with MCP-1 expression by human mesangial cells. Kidney Int 1995, 48:1263-1271[Medline]
receptors of human mesangial cells activates transcription factor nuclear factor-B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8 and IFN-inducible protein 10. J Immunol 1997, 159:3474-3482[Abstract]
B: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-11[Medline]
B pathway in the treatment of inflammation and cancer. J Clin Invest 2001, 107:135-142[Medline]
B kinase-ß. Nature 1998, 396:77-80[Medline]
B mobilization and TNF production in human monocytes. J Immunol 1993, 151:6986-6993[Abstract]
-induced NF-B activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am J Respir Cell Mol Biol 1998, 19:259-268B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995, 270:14255-14258B attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001, 89:899-906B in mouse glomerular mesangial cells in response to tumor necrosis factor-, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. J Clin Invest 1994, 94:1629-1636
B in experimental glomerulonephritis in rats. Biochem Biophys Acta 1996, 1316:132-138[Medline]
B in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IB family proteins. Hepatology 1999, 30:761-769[Medline]
B. J Exp Med 1996, 183:1829-1840B by preventing the degradation of IB- and IB-ß. J Biol Chem 1998, 273:1288-1297B by targeting the IB kinase complex. J Immunol 1999, 163:5617-5623R induces tyrosine phosphorylation of phospholipase C-1, phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells. J Immunol 1996, 156:4369-4376[Abstract]
and IL-6, and proliferation. J Immunol 1994, 153:5247-5255[Abstract]
B and AP-1 activation in human proteinuric renal disease. Kidney Int 2001, 60:1366-1377[Medline]
B activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999, 56:118-134[Medline]
B prevents carrageenan-induced inflammation in rat hind paw. Gene Therapy 2000, 7:1731-1737[Medline]
B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 2000, 120:59-65[Medline]
B plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 2001, 276:39713-39720B activation and RANTES expression in human U-251 MG astroglial cells. Brain Res Mol Brain Res 2001, 87:48-60[Medline]
This article has been cited by other articles:
 |
|
 |
|
  E. Sanchez-Lopez, S. Rayego, R. Rodrigues-Diez, J. S. Rodriguez, R. Rodrigues-Diez, J. Rodriguez-Vita, G. Carvajal, L. S. Aroeira, R. Selgas, S. A. Mezzano, et al. CTGF Promotes Inflammatory Cell Infiltration of the Renal Interstitium by Activating NF-{kappa}B J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1513 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Diaz Encarnacion, G. M. Warner, C. E. Gray, J. Cheng, H. K. H. Keryakos, K. A. Nath, and J. P. Grande Signaling pathways modulated by fish oil in salt-sensitive hypertension Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1323 - F1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Sanz, P. Justo, M. D. Sanchez-Nino, L. M. Blanco-Colio, J. A. Winkles, M. Kreztler, A. Jakubowski, J. Blanco, J. Egido, M. Ruiz-Ortega, et al. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation J. Am. Soc. Nephrol., April 1, 2008; 19(4): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hidaka, Y. Suzuki, M. Yamashita, T. Shibata, Y. Tanaka, S. Horikoshi, and Y. Tomino Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration Am. J. Pathol., March 1, 2008; 172(3): 603 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, L. Soltero, P. Zhang, X. R. Huang, H. Y. Lan, and H. J. Adrogue Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7 Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1123 - F1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Forslund, A. Sikio, and J. Anttinen IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2705 - 2708. [Full Text] [PDF]
|
|
|
|
|
|
Y. Ozawa and H. Kobori Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saadane, S. Masters, J. DiDonato, J. Li, and M. Berger Parthenolide Inhibits I{kappa}B Kinase, NF-{kappa}B Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 728 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Lopez-Franco, P. Hernandez-Vargas, G. Ortiz-Munoz, G. Sanjuan, Y. Suzuki, L. Ortega, J. Blanco, J. Egido, and C. Gomez-Guerrero Parthenolide Modulates the NF-{kappa}B-Mediated Inflammatory Responses in Experimental Atherosclerosis Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1864 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Liu and A. B. Malik NF-{kappa}B activation as a pathological mechanism of septic shock and inflammation Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L622 - L645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sugaru, T. Nakagawa, M. Ono-Kishino, J. Nagamine, T. Tokunaga, M. Kitoh, W. E. Hume, R. Nagata, and M. Taiji SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice Am J Physiol Renal Physiol, April 1, 2006; 290(4): F813 - F820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Jalal and B. C. Kone Src Activation of NF-{kappa}B Augments IL-1{beta}-Induced Nitric Oxide Production in Mesangial Cells J. Am. Soc. Nephrol., January 1, 2006; 17(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamada, S. Katsuma, T. Adachi, A. Hirasawa, S. Shiojima, T. Kadowaki, Y. Okuno, T.-a. Koshimizu, S. Fujii, Y. Sekiya, et al. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis PNAS, May 24, 2005; 102(21): 7736 - 7741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pullerits, M. Bokarewa, I.-M. Jonsson, M. Verdrengh, and A. Tarkowski Extracellular cytochrome c, a mitochondrial apoptosis-related protein, induces arthritis Rheumatology, January 1, 2005; 44(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Esteban, O. Lorenzo, M. Ruperez, Y. Suzuki, S. Mezzano, J. Blanco, M. Kretzler, T. Sugaya, J. Egido, and M. Ruiz-Ortega Angiotensin II, via AT1 and AT2 Receptors and NF-{kappa}B Pathway, Regulates the Inflammatory Response in Unilateral Ureteral Obstruction J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1514 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Heckmann, C. Waltzinger, P. Jolicoeur, M. Dreano, M. H. Kosco-Vilbois, and Y. Sagot IKK2 Inhibitor Alleviates Kidney and Wasting Diseases in a Murine Model of Human AIDS Am. J. Pathol., April 1, 2004; 164(4): 1253 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Martin-Ventura, L. M. Blanco-Colio, B. Munoz-Garcia, A. Gomez-Hernandez, A. Arribas, L. Ortega, J. Tunon, and J. Egido NF-{kappa}B Activation and Fas Ligand Overexpression in Blood and Plaques of Patients With Carotid Atherosclerosis: Potential Implication in Plaque Instability Stroke, February 1, 2004; 35(2): 458 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pocock, C. Gomez-Guerrero, S. Harendza, M. Ayoub, P. Hernandez-Vargas, G. Zahner, R. A. K. Stahl, and F. Thaiss Differential Activation of NF-{kappa}B, AP-1, and C/EBP in Endotoxin-Tolerant Rats: Mechanisms for In Vivo Regulation of Glomerular RANTES/CCL5 Expression J. Immunol., June 15, 2003; 170(12): 6280 - 6291. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or containing LPS/cytokines (
). Data of luciferase activity were normalized to Renilla activity and protein amounts, and are expressed as fold increases, compared with control. C: The NO production at 24 hours in medium alone (
) and in healthy control rats receiving saline (
) was analyzed daily and expressed in mg/24 hours (*, P < 0.05 versus untreated nephritic rats). B and C: Representative micrographs show morphological changes at day 7 in untreated nephritic (B) and gliotoxin-treated rat (C). Original magnifications, x200.
